FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of pharmaceutics and represents a method of treating a patient with locally advanced or metastasising solid tumours, which includes the introduction of a therapeutic combination as a combined composition or by the alternation of components to a mammal, with the therapeutic composition including a therapeutically effective quantity of phosphatidylinositol-3-kinase (PI3K) or its pharmaceutically acceptable salt, and a therapeutically effective quantity of an inhibitor of a mitogen-activated proteinkinase kinase (MEK) or its pharmaceutically acceptable salt.
EFFECT: invention provides a synergic effect in the combined application of active agents in the treatment of locally advanced or metastasising solid tumours.
5 cl, 7 ex, 2 tbl, 7 dwg
| Title |
Year |
Author |
Number |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
2013 |
- Belvin Marsiya
- Fridman Lori
- Sampat Dipak
- Vallin Dzheffri
|
RU2665949C2 |
| DETERMINATION OF CELL SENSITIVITY TO TREATMENT WITH B-Raf INHIBITOR BY DETECTION OF K-ras MUTATION AND LEVELS OF RTK EXPRESSION |
2010 |
- Khatzivassiliu Dzhordzhija
- Malek Shiva
|
RU2553379C2 |
| COMBINATION OF (A) PHOSPHOINOSITIDE-3-KINASE INHIBITOR AND (B) Ras/Raf/Mek PATHAWAY MODULATOR |
2009 |
- Garsija-Ehcheverrija Karlos
- Mera Sove-Mishel'
- St'Juart Darrin
- Vi S'Jusan
- Frich Kristine
- Nejdzhel Tobi
|
RU2508110C2 |
| COMBINATIONS OF INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND CHEMIOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION |
2008 |
- Belvin Marsija
- Fridman Lori
- Kheflikh Klaus
- Sampat Dipak
- Vidzhapurkar Ulka
- Vallin Dzheffri
- Dzhonson Lejza
- Singkh Mallika
- Patel' Sonal'
|
RU2523890C2 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT |
2018 |
- Nichols, Robert J.
- Goldsmith, Mark A.
- Schulze, Christopher
- Smith, Jacqueline
- Wildes, David E.
- Kelsey, Stephen
- Singh, Mallika
|
RU2805355C2 |
| METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION |
2014 |
- Abe Tetsuya
- Itadani Khiraku
|
RU2666921C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR |
2017 |
- Caponigro, Giordano
- Meyer, Matthew John
- Cooke, Vesselina
- Stuart, Darrin
|
RU2774612C2 |
| COMBINATIONS OF ANTIBODY DRUG CONJUGATES AND CHEMOTHERAPEUTIC COMPOUNDS AND METHODS FOR USING |
2009 |
- Berri Linn
- Fillips Gejl L'Juis
- Slivkovski Mark Ks.
|
RU2510272C2 |
| COMBINATIONS OF ANTI-HER2-ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC REMEDIES, AND APPLICATION METHODS |
2018 |
- Berry, Leanne
- Phillips, Gail, Lewis
- Sliwkowski, Mark, X.
|
RU2781195C2 |
| COMBINATIONS OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF USE |
2013 |
- Berri Linn
- Fillips Gejl Lyuis
- Slivkovski Mark Ks.
|
RU2671489C2 |
